For instance, researchers have studied targeted RTK therapy for melanoma (Sabbah et al. 2021), as well as targeting the RTK‐PI3K‐mTOR pathway for glioblastoma treatments (Colardo et al. 2021). This evidence concerns the gene MTOR and glioblastoma.